Results 31 to 40 of about 1,978 (184)
Expanding access to a choice-based multi-method PrEP market for HIV prevention. [PDF]
J Int AIDS SocJournal of the International AIDS Society, Volume 28, Issue S2, July 2025.
Naidoo NP, Ayieko J, Fonner VA.
europepmc +2 more sources
The dapivirine vaginal ring from the perspective of married men in Uganda [PDF]
African Journal of AIDS Research, 2021 Background: Men play a key role in influencing uptake of women's health products, such as female condoms and vaginal microbicides used for family planning and HIV prevention.Method: We explored men's perceptions of the dapivirine vaginal ring (DVR), a vaginal microbicide, in Kalungu District, rural south-western Uganda.
Anita Kabarambi +6 more
openaire +2 more sources
Contemporary Clinical Trials Communications, 2021 Safe practices for dispensing investigational product (IP) during clinical trials are not standardized and information in this regard is often limited.
Cindy Jacobson +12 more
doaj +1 more source
Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis
Southern African Journal of HIV Medicine, 2023 The number of products that can provide pre-exposure prophylaxis (PrEP) for HIV prevention is expanding, with three now approved in South Africa (oral Tenofovir-based PrEP, injectable Cabotegravir, and a Dapivirine-based vaginal ring) and more in the ...
Carey Pike +2 more
doaj +1 more source
Dapivirine-releasing vaginal rings produced by plastic freeforming additive manufacturing [PDF]
International Journal of Pharmaceutics, 2019 Here we report the first use of an additive manufacturing (AM) technique based on high pressure material jetting of molten thermoplastic for the fabrication of dapivirine (DPV) loaded vaginal rings (VRs). The VRs are compared to those produced conventionally using injection molding (IM).
Nicole R. Welsh +3 more
openaire +4 more sources
Multipurpose vaginal rings for HIV prevention and non-hormonal contraception
British Journal of Pharmacy, 2022 Vaginal rings releasing antiretrovirals - either alone or in combination with contraceptive progestins - are being developed for contraception and prevention of human immunodeficiency virus (HIV) transmission via vagina.
Xin Shen +4 more
doaj +1 more source
WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis [PDF]
, 2014 Introduction: Two new microbicide products based on topical (vaginal) application of antiretroviral drugs – 1% tenofovir gel and the dapivirine ring – are currently in late-stage clinical testing, and results on their safety and effectiveness are ...
Elizabeth McGrory +13 more
core +8 more sources
International Journal of Pharmaceutics: X, 2021 Vaginal rings releasing antiretrovirals – either alone or in combination with contraceptive progestins – are being developed for prevention of human immunodeficiency virus (HIV) transmission via vaginal sex.
Clare F. McCoy +9 more
doaj +1 more source
Optimization of diarylazines as anti-HIV agents with dramatically [PDF]
, 2013 Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity.
Anderson, Karen S. +4 more
core +1 more source
Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda [PDF]
Sexually Transmitted Infections, 2021 ObjectivesParticipation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.MethodsWe used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at ...
Sylvia Kusemererwa +4 more
openaire +2 more sources